Search results
Showing 1 to 3 of 3 results for tildrakizumab
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Source guidance details Comes from guidance Tildrakizumab for treating moderate to severe plaque psoriasis Number TA575